HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shares dropped 0.6% on Friday . The company traded as low as C$5.00 and last traded at C$5.00. Approximately 1,765 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 13,170 shares. The stock had previously closed at C$5.03.
HLS Therapeutics Stock Performance
The stock has a market capitalization of C$111.24 million, a P/E ratio of -5.01 and a beta of 1.07. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The stock's fifty day moving average price is C$4.92 and its two-hundred day moving average price is C$4.52.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
